Abstract

Photodynamic therapy (PDT) is an established therapeutic modality for the management of cancers. Conjugation with tumor-specific small molecule ligands (e.g., short peptides or peptidomimetics) could increase the tumor targeting of PDT agents, which is very important for improving the outcome of PDT. However, compared with antibody molecules, small molecule ligands have a much weaker affinity to their receptors, which means that their tumor enrichment is not always ideal. In this work, we synthesized multimeric RGD ligand-coupled conjugates of pyropheophorbide-a (Pyro) to increase the affinity through multivalent and cluster effects to improve the tumor enrichment of the conjugates. Thus, the dimeric and trimeric RGD peptide-coupled Pyro conjugates and the monomeric one for comparison were efficiently synthesized via a convergent strategy. A short polyethylene glycol spacer was introduced between two RGD motifs to increase the distance required for multivalence. A subsequent binding affinity assay verified the improvement of the binding towards integrin αvβ3 receptors after the increase in the valence, with an approximately 20-fold improvement in the binding affinity of the trimeric conjugate compared with that of the monomeric conjugate. In vivo experiments performed in tumor-bearing mice also confirmed a significant increase in the distribution of the conjugates in the tumor site via multimerization, in which the trimeric conjugate had the best tumor enrichment compared with the other two conjugates. These results indicated that the multivalence interaction can obviously increase the tumor enrichment of RGD peptide-conjugated Pyro photosensitizers, and the prepared trimeric conjugate can be used as a novel antitumor photodynamic agent with high tumor enrichment.

Highlights

  • Photodynamic therapy (PDT) is an established therapeutic modality for the treatment of a variety of premalignant and malignant diseases [1,2]

  • Solving the tumor enrichment problem is very important for its clinical application

  • We adopted a convergent strategy in which we used a solid-phase strategy based on Fmoc chemistry to prepare the cyclic RGD peptide molecule with a carboxylic group that is free for conjugation and with all other groups protected

Read more

Summary

Introduction

Photodynamic therapy (PDT) is an established therapeutic modality for the treatment of a variety of premalignant and malignant diseases [1,2]. The cyclic peptide cyclo(-RGDfK-), which contains a conformationally restrained RGD sequence, has been often used for targeting tumor imaging and/or therapeutic agents as a high affinity ligand for the αv β3 integrin receptor [23,24,25,26,27,28,29,30,31] This conjugate showed improved tumor enrichment compared to free Pyro, greatly improving the PDT outcome against tumors in a mouse model and destroying implanted tumors with only one or two treatments of PDT. Until now, not much attention has been paid to preparing the conjugates of photosensitizers with multimeric ligands To this end, we hope to adopt a multivalence strategy to improve the tumor enrichment capability of the RGD-coupled Pyro photosensitizer to enhance its clinical application potential

Molecular Design
Solid-Phase Synthesis of Side Chain-Protected Cyclic RGD Pentapeptide 1 and 2
Synthesis of Mono-RGD Conjugate Pyro-MonoRGD
Synthetic
Photophysical and Photochemical Properties
Receptor Binding Assay
In Vivo Distribution
Instruments and Materials
Solid-Phase Synthesis of Side Chain-Protected Cyclic RGD Pentapeptide
Synthesis of Amino-Modified Cyclic Pentapeptide
Synthesis of Monomeric RGD Conjugate Pyro-MonoRGD
Synthesis of Pyro-Conjugated Dimeric Linker 7
Synthesis of Conjugate Pyro-DiRGD
3.11. Synthesis of Pyro-Conjugated Compound
3.12. Synthesis of Deprotected Pyro-Conjugated Trimeric Linker
3.13. Synthesis of the Trimeric Conjugate Pyro-TriRGD
3.14. Determination of the Photophysical and Photochemical Properties
3.15. Receptor Binding Assay
3.16. In Vivo Tumor Enrichment Analysis
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call